Table 1.

Characteristics of included studies.

StudyFollowup, moIntervention/ComparisonPopulationRouteMean Age, yrs; M/FPrimary OutcomeSecondary Outcomes
De Boer 2008443100 units Botox® vs placeboPost-stroke shoulder spasticityIM59; 12/9Pain VAS, external rotation
Kong 2007453500 units Dysport™ vs placeboPost-stroke shoulder spasticityIM52; n = 17Pain VASMuscle tone, shoulder abduction
Lim 2008463100 units Botox® vs triamcinolone acetonidePost-stroke shoulder spasticityIM61; 15/14Pain NRS, physician global, shoulder ROMSpasticity, adverse events, arm function
Marco 2007476TENS + 500 units Dysport™ vs TENS + placeboPost-stroke shoulder spasticityIM66; 21/8Pain VASSpasticity, shoulder ROM
Yelnik 2007481500 units Dysport™ vs placeboPost-stroke shoulder spasticityIM54 15/5Pain VAS, spasticity, use of analgesics, ROM, spasticity
Singh 2009491100 units Botox® vs placeboOA, RAIA71; 35/1Pain VASDropout, shoulder disability, global scale, quality of life, adverse events
  • VAS: visual analog scale; NRS: numeric rating scale; IM: intramuscular; IA: intraarticular; OA: osteoarthritis; RA: rheumatoid arthritis. ROM: range of motion.